COMMUNIQUÉS West-GlobeNewswire

CVRx Reports Third Quarter 2026 Financial and Operating Results
05/11/2026
MINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
05/11/2026
Strengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer On track for topline data readout from the pivotal Phase 3 NOVA-2 trial of LB [...]
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
05/11/2026
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 5, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation [...]
Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results
05/11/2026
Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027 Expanded intellectual property portfolio with new European patent [...]
AVITA Medical Reports Third Quarter Results
05/11/2026
Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic [...]
The Joint Corp. Reports Third Quarter 2026 Financial Results
05/11/2026
- Revenue Increases to $13.6 Million - - Net Income from Continuing Operations Increases by $1.2 Million to $1.5 Million and Adjusted EBITDA From Continuing Operations Increases by $0.9 Million to $2.3 Million - - [...]
Sight Sciences to Present at Two Upcoming Investor Conferences
05/11/2026
MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
ASHA Responds to New Speech-Language Pathology Treatment Codes in 2027 Medicare Physician Fee Schedule
05/11/2026
Throughout the development of this coding change, ASHA’s advocacy prioritized ensuring that speech-language pathology services are accurately described, appropriately valued, and supported by payment policies that [...]
EmblemHealth Distributes More Than 62,000 Bags of Food as Food Insecurity Continues To Grow Across New York City
05/11/2026
EmblemHealth’s Community Food Security Program reaches New Yorkers through nearly 400 events and a network of 115 food access partners PHOTO: EmblemHealth staff assist community members at a Neighborhood Care event [...]
Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
05/11/2026
Trial met primary endpoint with a statistically significant reduction in microglial activation on TSPO PET (p=0.0168) Intranasal foralumab is the first non-invasive anti-CD3 therapy that has shown a favorable safety and [...]
What Published Human Trials Show About a Postbiotic in Women Ages 40 to 55
05/11/2026
Three peer-reviewed studies behind the two ingredients in Calroy Health Sciences’ Selentra HP™ measured inflammatory markers, skin health, and bone mineral density in women during and after the menopause transition. [...]
Scipher Medicine and Grupo Amarey Announce First PrismRA® Patient Tests Completed in Colombia
05/11/2026
DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine, a leading precision medicine company, today announced that the first patient tests under its strategic partnership with Grupo Amarey have been [...]
GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update
05/11/2026
Cash and cash equivalents of €95.6 million as of September 30, 2026; expected to fund the Company beyond 2028, with continued revenue growth and disciplined spending thereafter expected to drive GENFIT toward [...]
GENFIT : Information financière du troisième trimestre 2026 et point sur les activités de la Société
05/11/2026
La trésorerie et les équivalents de trésorerie s’élèvent à 95,6 millions d’euros au 30 septembre 2026 et permettent un financement des activités au-delà de fin 2028. La croissance attendue des revenus futurs, combinée [...]
Significant growth in both revenue and earnings
05/11/2026
ANNOUNCEMENT NR. 325 5 November 2026 Trading statement for Q1 2026/27 (1 July – 30 September 2026) Significant growth in both revenue and earnings Revenue was up by 28% in Q1 2026/27 to DKK 160.0 million from DKK 124.6 [...]
RAMSAY SANTE : Unaudited interim results at the end of September 2026
05/11/2026
PRESS RELEASE Paris, 5 th November 2026 Unaudited interim results at the end of September 2026 Ramsay Santé delivers solid first-quarter performance, with continued revenue growth and improved operational performance [...]
RAMSAY SANTE : résultats intermédiaires au 30 septembre 2026
05/11/2026
COMMUNIQUÉ DE PRESSE Paris, 5 novembre 2026 Résultats trimestriels non audités à fin septembre 2026 Ramsay Santé affiche une solide performance au premier trimestre, avec une croissance continue de son chiffre d’ [...]
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
05/11/2026
Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting ® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO ® [...]
Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL
05/11/2026
Les résultats de l’étude ELSPIRE seront présentés en «late-breaking» lors de The Liver Meeting ® 2026 et publiés simultanément dans la revue phare de l’AASLD, HEPATOLOGY À la semaine 52, 85,3 % des patients recevant [...]

Pages